- Home
- NBTX vs FINW Comparison
NBTX vs FINW Comparison
Compare NBTX & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- FINW
- Stock Information
- Founded
- NBTX 2003
- FINW 1999
- Country
- NBTX France
- FINW United States
- Employees
- NBTX N/A
- FINW N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- FINW Commercial Banks
- Sector
- NBTX Health Care
- FINW Finance
- Exchange
- NBTX Nasdaq
- FINW Nasdaq
- Market Cap
- NBTX 211.9M
- FINW 196.2M
- IPO Year
- NBTX 2020
- FINW 2021
- Fundamental
- Price
- NBTX $4.57
- FINW $15.58
- Analyst Decision
- NBTX Strong Buy
- FINW Buy
- Analyst Count
- NBTX 1
- FINW 4
- Target Price
- NBTX $8.00
- FINW $20.75
- AVG Volume (30 Days)
- NBTX 7.1K
- FINW 74.9K
- Earning Date
- NBTX 04-02-2025
- FINW 07-24-2025
- Dividend Yield
- NBTX N/A
- FINW N/A
- EPS Growth
- NBTX N/A
- FINW N/A
- EPS
- NBTX N/A
- FINW 0.91
- Revenue
- NBTX N/A
- FINW $72,056,000.00
- Revenue This Year
- NBTX N/A
- FINW $38.17
- Revenue Next Year
- NBTX $221.06
- FINW $18.44
- P/E Ratio
- NBTX N/A
- FINW $16.49
- Revenue Growth
- NBTX N/A
- FINW 7.66
- 52 Week Low
- NBTX $2.76
- FINW $10.27
- 52 Week High
- NBTX $6.00
- FINW $20.94
- Technical
- Relative Strength Index (RSI)
- NBTX 52.43
- FINW 66.00
- Support Level
- NBTX $4.31
- FINW $13.81
- Resistance Level
- NBTX $5.00
- FINW $15.65
- Average True Range (ATR)
- NBTX 0.25
- FINW 0.53
- MACD
- NBTX -0.06
- FINW 0.19
- Stochastic Oscillator
- NBTX 24.44
- FINW 96.48
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.